ArticleRMD open2020
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.
Mittal Shah et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this paperpooled ittrialcites it